DoD Peer Reviewed Orthopaedic, Clinical Translational Research Award | W81XWH 21 PRORP CTRA

Opportunity Information: Apply for W81XWH 21 PRORP CTRA

The Department of Defense (DoD) Peer Reviewed Orthopaedic Research Program (PRORP) Clinical Translational Research Award (CTRA) is a funding opportunity designed to move promising orthopaedic ideas into real-world clinical use, especially where the work is not yet ready for a large, definitive randomized controlled trial. The emphasis is on high-impact clinical research that can realistically change how orthopaedic injuries are diagnosed, treated, rehabilitated, or prevented. Applicants are expected to show how their project could influence standards of care in the near term and over the long term, and how it could strengthen evidence-based guidelines relevant to military Service members, Veterans, and civilian patients dealing with orthopaedic injuries.

A central theme of the CTRA is translation: taking current or emerging techniques, interventions, or clinical approaches and testing or refining them in human clinical settings to better serve military needs. The opportunity highlights outcomes that matter to patients and readiness, such as health, function, and quality of life after injury. Another stated goal is practical decision support, meaning the research should help identify what works best (and for whom) across diagnosis, treatment, rehabilitation, and prevention, with results that are useful not only to clinicians and patients but also to caregivers and policymakers.

This award mechanism is broader than the program’s separate Clinical Trial Award (CTA). The CTA is limited strictly to clinical trials, while the CTRA supports a wider range of clinical research as long as it stays within human-focused clinical boundaries. CTRA projects may be interventional and may include some retrospective analysis, but proposals cannot be purely retrospective or focused only on database mining. Small pilot clinical trials are allowed, which makes this mechanism a fit for early-to-mid stage clinical translation where feasibility, preliminary efficacy, optimization of endpoints, or refinement of clinical protocols still needs to be established before a larger trial is justified. Animal research is explicitly not allowed under this opportunity; applicants needing animal work are directed to a different PRORP mechanism.

The announcement uses the CDMRP definition of clinical research, which includes patient-oriented research involving direct interaction with human subjects (or identifiable human-origin materials), as well as epidemiologic, behavioral, outcomes, and health services research. At the same time, it draws a line around certain types of secondary-use research: studies that fall under IRB Exemption 4 (research using existing, publicly available or otherwise fully de-identified data/specimens) are not considered CDMRP-defined clinical research for this mechanism. In practice, that means investigators need a clear clinical research component involving patients and/or non-exempt human-subjects research activities rather than relying entirely on de-identified datasets.

If a project involves a clinical trial, the opportunity follows the standard definition: human subjects are prospectively assigned to one or more interventions (including placebo or controls) to evaluate effects on health-related outcomes. The announcement also flags regulatory expectations for investigational products. If a study uses a drug that is not FDA-approved for the proposed use, an Investigational New Drug (IND) application may be required, and if required it must be submitted within 12 months of the award date (with documentation from the IRB or FDA if an IND is not needed). Similar requirements apply to investigational devices through an Investigational Device Exemption (IDE), including the possibility of an abbreviated IDE when appropriate. If an investigational product trial will run at international sites, the relevant host-country regulatory submissions must also be made within 12 months. The DoD reserves the right to withdraw funding if required IND/IDE or international regulatory submissions are not made on time, so regulatory strategy and timelines are not a side detail here; they are a core feasibility issue.

Military and Veteran relevance is a required framing element. Every application must clearly explain why the work matters to military and/or Veteran populations affected by orthopaedic injury. Including active-duty Service members or Veterans as participants is encouraged but not mandatory, and collaboration with military or VA clinicians and researchers is also encouraged. Reviewers are looking for projects that speak to combat-related injuries as well as non-battle orthopaedic injuries that still affect readiness, return to duty, and return to work.

The opportunity sets expectations for what a strong application should include. Preliminary data relevant to the proposed clinical research is required, signaling that the DoD wants projects with a credible starting evidence base rather than purely speculative concepts. The study must be grounded in sound scientific rationale supported by a thoughtful review of existing literature. Applicants need to show they can actually execute the study, including real access to an appropriate patient population, a believable accrual plan, and an understanding of how existing standards of care might shape enrollment, comparison groups, and interpretation. If the project uses a drug, device, or other intervention materials, the proposal should document reliable access for the full study duration and address product quality and stability in a way that matches applicable FDA manufacturing expectations (for example GMP and related quality system requirements).

Operational rigor is heavily emphasized. Proposals should present clear objectives and well-justified endpoints or outcome measures, with design choices aligned to Good Clinical Practice (GCP). A detailed statistical analysis plan is expected, along with appropriate statistical expertise on the team and a power analysis tied to sample size projections that can genuinely answer the study questions. Applicants must also include a data management plan and describe the database approach that will protect data integrity; if the research is FDA-regulated, the database must be 21 CFR Part 11 compliant and follow appropriate data standards. In addition, the DoD expects a safety management plan (pharmacovigilance when applicable) and a clinical monitoring plan that explains how compliance and study conduct will be monitored across sites. The announcement also calls for a study coordinator role to shepherd IRB and regulatory processes, coordinate multi-site activities, and manage participant accrual, reflecting the program’s preference for professionally run clinical research operations rather than informal, investigator-only management.

The CTRA also asks applicants to think beyond the grant period. A transition plan is required to show how the intervention, product, or approach would move to the next clinical phase and/or toward market delivery after successful completion. The application should demonstrate strong institutional support or an industry partnership, and when relevant it should identify who will serve as the FDA regulatory sponsor and accept the sponsor responsibilities described in 21 CFR 312. This makes it clear the program is not only funding data collection; it is funding a pathway toward adoption, scale, and real clinical impact.

For funded projects that include a clinical trial, there are additional transparency and registration requirements. Investigators must register applicable trials on ClinicalTrials.gov prior to study initiation, and they must post a copy of the IRB-approved informed consent form on a publicly available federal website as required under federal human subjects regulations (referenced in 32 CFR 219). These requirements align the award with broader federal expectations around trial transparency and participant protection.

On the funding and award structure, the DoD issues these awards as assistance agreements, meaning either grants or cooperative agreements. Which one you receive depends on how much substantial involvement the DoD anticipates during performance. If the agency expects minimal involvement, it will use a grant; if it expects collaboration, participation, or intervention during the work, it will use a cooperative agreement, and the specific involvement will be spelled out in the award terms. For FY21, the anticipated maximum total cost per award for the full period of performance is capped at $1.5 million. Program-wide, the DoD anticipated roughly $7.5 million total to fund about five awards, with selections depending on available funds and the scientific and programmatic merit of submitted applications. The posted timeline notes the original application closing date as September 10, 2021, and indicates awards were expected no later than September 30, 2022, using FY21 funds that would remain available for obligation within the applicable federal funding lifecycle (noted as expiring for use on September 30, 2027).

In plain terms, this opportunity is aimed at clinically grounded orthopaedic research that is ready to be tested with patients, is supported by real preliminary evidence, and is built with the regulatory, statistical, operational, and translational planning needed to produce results that can actually change practice for Service members, Veterans, and the broader orthopaedic patient population.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Orthopaedic, Clinical Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 01, 2021.
• Applicants must submit their applications by Sep 10, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PRORP CTRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: